Literature DB >> 23375537

Clinical utility of different botulinum neurotoxin preparations.

Steven B Abrams1, Mark Hallett.   

Abstract

Comparative literature assessing the relative safety and efficacy of different BoNT products is limited. The quantity and quality of data vary by preparation and indication. Clinicians seeking data relevant to the care of patients with specific conditions may find only reports about small numbers of patients with varying symptoms. While a literature search for "botulinum neurotoxins" will yield a large number of publications; only a fraction of these meet criteria for an academic evidence-based review. Patients may have been treated with a different BoNT formulation than that with which the physician is familiar, or there may be little or no clinical data on the use of a specific BoNT product for the proposed intervention. This paper is an introduction to a series of papers (which follow) in which an expert panel reviewed the BoNT clinical trial literature in order to provide evidence-based recommendations regarding the clinical use and efficacy of available BoNT preparations for four major therapeutic areas: movement disorders, spasticity, urology, and secretory disorders. Expert opinion is also included to address practical issues where more evidence and further research is needed.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23375537     DOI: 10.1016/j.toxicon.2012.11.024

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  5 in total

1.  Clinical Response to IncobotulinumtoxinA, after Demonstrated Loss of Clinical Response to OnabotulinumtoxinA and RimabotulininumtoxinB in a Patient with Musician's Dystonia.

Authors:  Vesper Fe Marie Llaneza Ramos; Barbara I Karp; Codrin Lungu; Katharine Alter; Mark Hallett
Journal:  Mov Disord Clin Pract       Date:  2014-09-30

Review 2.  Botulinum neurotoxin type A for the treatment of pain: not just in migraine and trigeminal neuralgia.

Authors:  Giorgio Sandrini; Roberto De Icco; Cristina Tassorelli; Nicola Smania; Stefano Tamburin
Journal:  J Headache Pain       Date:  2017-03-21       Impact factor: 7.277

3.  Toward more focused multimodal and multidisciplinary approaches for pain management in Parkinson's disease.

Authors:  Arturo Cuomo; Anna Crispo; Andrea Truini; Silvia Natoli; Orazio Zanetti; Paolo Barone; Marco Cascella
Journal:  J Pain Res       Date:  2019-07-22       Impact factor: 3.133

4.  Snake and Spider Toxins Induce a Rapid Recovery of Function of Botulinum Neurotoxin Paralysed Neuromuscular Junction.

Authors:  Elisa Duregotti; Giulia Zanetti; Michele Scorzeto; Aram Megighian; Cesare Montecucco; Marco Pirazzini; Michela Rigoni
Journal:  Toxins (Basel)       Date:  2015-12-08       Impact factor: 4.546

Review 5.  Therapeutic Applications of Botulinum Neurotoxin for Autonomic Symptoms in Parkinson's Disease: An Updated Review.

Authors:  Steven D Mitchell; Christos Sidiropoulos
Journal:  Toxins (Basel)       Date:  2021-03-19       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.